mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: BRCA1 Mutation Carrier|BRCA2 Mutation Carrier|Endometrial Adenocarcinoma|Estrogen Receptor Negative|HER2/Neu Negative|High Grade Ovarian Serous Adenocarcinoma|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Recurrent Uterine Corpus Carcinoma|Stage III Uterine Corpus Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Uterine Corpus Cancer AJCC v7|Triple-Negative Breast Carcinoma
Interventions: DRUG: Capivasertib|OTHER: Laboratory Biomarker Analysis|DRUG: Olaparib|OTHER: Pharmacological Study|DRUG: Vistusertib
Sponsor: M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)